consent for semaglutide GLP-1 Informed & Risk Disclosure Kit GLP-1 Informed Consent & Risk
Description
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial
A treatment for non-alcoholic fatty liver disease that incorporates a metabolite found in the gut could prevent progression to a more serious liver condition
Eli Lillys once-daily Foundayo is the second obesity pill to receive FDA approval
Read Does Where You Inject Your GLP-1 Shot Matter
| 27 comments on LinkedIn
Ensure your weight loss, heart health, and diabetes are effectively managed
